167 related articles for article (PubMed ID: 37594126)
1. RBM15‑mediating MDR1 mRNA m
Yuan J; Guan W; Li X; Wang F; Liu H; Xu G
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594126
[TBL] [Abstract][Full Text] [Related]
2. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
3. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
4. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
5. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
6. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract][Full Text] [Related]
7. Knockdown RBM15 Inhibits Colorectal Cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6A) Modification of MyD88 mRNA.
Zhang Z; Mei Y; Hou M
Cancer Biother Radiopharm; 2022 Dec; 37(10):976-986. PubMed ID: 34842457
[TBL] [Abstract][Full Text] [Related]
8. RBM15 suppresses hepatic insulin sensitivity of offspring of gestational diabetes mellitus mice via m6A-mediated regulation of CLDN4.
Fang J; Wu X; He J; Zhang H; Chen X; Zhang H; Novakovic B; Qi H; Yu X
Mol Med; 2023 Feb; 29(1):23. PubMed ID: 36803098
[TBL] [Abstract][Full Text] [Related]
9. RBM15 Knockdown Impairs the Malignancy of Cervical Cancer by Mediating m6A Modification of Decorin.
Wang H; Li C; Wei Q; Zhang E; Yang Y; Sha L; Wang D
Biochem Genet; 2024 Mar; ():. PubMed ID: 38429603
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer.
Zhang C; Gu L; Xiao J; Jin F
BMC Cancer; 2023 Jul; 23(1):684. PubMed ID: 37474926
[TBL] [Abstract][Full Text] [Related]
11. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
[TBL] [Abstract][Full Text] [Related]
12. Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.
Guan W; Yuan J; Li X; Gao X; Wang F; Liu H; Shi J; Xu G
J Cancer; 2023; 14(13):2538-2551. PubMed ID: 37670966
[TBL] [Abstract][Full Text] [Related]
13. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
14. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
15. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of N6-methyladenosine RBM15 regulators in lung adenocarcinoma.
Ma M; Wang W; Wang B; Yang Y; Huang Y; Zhao G; Ye L
Cell Mol Biol (Noisy-le-grand); 2022 May; 68(1):130-139. PubMed ID: 35809319
[TBL] [Abstract][Full Text] [Related]
19. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
20. RBM15-Mediated m6A Modification of K17 Affects Keratinocytes Response to IL-17A Stimulation in Psoriasis.
Fu M; Zhou B; Shi N; Dong R; Chen Y
Ann Clin Lab Sci; 2023 Jul; 53(4):529-538. PubMed ID: 37625827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
